DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Uroqid-Acid (Methenamine Mandelate / Sodium Acid Phosphate) - Description and Clinical Pharmacology

 
 



DESCRIPTION

Each UROQID-Acid® No.2 tablet contains methenamine mandelate 500 mg and sodium acid phosphate, monohydrate 500 mg.

CLINICAL PHARMACOLOGY

Methenamine mandelate is rapidly absorbed and excreted in the urine. Formaldehyde is released by acid hydrolysis from methenamine with bactericidal levels rapidly reached at pH 5.0-5.5. Proportionally less formaldehyde is released as urinary pH approaches 6.0 and insufficient quantities are released above this level for therapeutic response. In acid urine, mandelic acid exerts its antibacterial action and also contributes to the acidification of the urine. Mandelic acid is excreted by both glomerular filtration and tubular excretion. In acid urine, there is equally effective antibacterial activity against both gram-positive and gram-negative organisms, since the antibacterial action of mandelic acid and formaldehyde is nonspecific. With Proteus vulgaris and urea splitting strains of Pseudomonas and Aerobacter, results may be discouraging and particular attention is required in monitoring urinary pH and overall management.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017